About this item:

382 Views | 0 Downloads

Author Notes:

Corresponding author: rschina@emory.edu

RFS is a founder and major shareholder of Idenix Pharmaceuticals, Pharmasset Inc. and RFS Pharma. CG declares no competing interests.

Subjects:

Research Funding:

National Institutes of Health

Department of Veterans Affairs

Antiretroviral therapy in macrophages: implication for HIV eradication

Tools:

Journal Title:

Antiviral Chemistry and Chemotherapy

Volume:

Volume 20, Number 2

Publisher:

, Pages 63-78

Type of Work:

Article | Post-print: After Peer Review

Abstract:

HIV type-1 (HIV-1) accounts for more than 25 million deaths and nearly 40 million people are infected worldwide. A significant obstacle in clearing virus from infected individuals is latently infected viral reservoirs. Latent HIV-1 can emerge with recrudescence as a productive infection later in disease progression and could provide a source for the emergence of resistant HIV-1. It is widely recognized that macrophages represent a latently infected viral reservoir and are a significant and critical HIV-1 target cell in vivo. Macrophages can be divided into multiple subsets of macrophage-like cells, all of which are susceptible to HIV-1 infection, including dendritic cells, Langerhans cells, alveolar macrophages, mucosal macrophages and microglial cells. Current antiretroviral therapy (ART) often displays differential antiviral activity in macrophages relative to CD4+ T-lymphocytes. Significant work has been performed to establish antiviral activity of many clinically approved ART in macrophages; however, a direct link between antiviral activity and specific mechanisms responsible for these antiviral effects are incompletely understood. This review identifies many understudied areas of research, along with topics for further research in the field of HIV therapy and eradication. Discussion focuses upon the known cellular pharmacology and antiviral activity of antiretroviral agents in macrophages and its relationship to latency, chronic HIV-1 infection and therapeutic strategies to eradicate systemic HIV-1 infection.

Copyright information:

©2009 International Medical Press

Export to EndNote